Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search

Pages

173545 items
12:38 PM, Oct 19, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Oxford Nanopore receives £50M investment from Amgen

Oxford Nanopore Technologies Ltd. (Oxford, U.K.) received an equity investment of £50 million ($65.6 million) on Oct. 18 from Amgen Inc. (NASDAQ:AMGN). Amgen's deCODE Genetics subsidiary uses Oxford Nanopore's nanopore-based DNA and RNA sequencing technology to...
12:37 PM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Regulatory

FDA panel votes in favor of Shire’s constipation product

FDA’s Gastrointestinal Drugs Advisory committee voted unanimously in favor of approving an NDA from Shire plc (LSE:SHP; NASDAQ:SHPG) for prucalopride to treat chronic idiopathic constipation (CIC). Its PDUFA date is Dec. 21. The panel voted 10-0...
12:35 PM, Oct 19, 2018  |  BC Week In Review | Company News  |  Deals

Sarepta gets gene therapy candidate, Lysogene extends runway

Lysogene S.A. (Euronext:LYS) granted Sarepta Therapeutics Inc. (NASDAQ:SRPT) exclusive, ex-European rights to LYS-SAF302, an adeno-associated virus (AAV)-mediated gene therapy. Sarepta will pay $15 million up front and make a $2.5 million equity investment in Lysogene,...
12:34 PM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

BioLineRx reports response, survival data for BL-8040, Keytruda combo in pancreatic cancer

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) reported data from the Phase IIa COMBAT/KEYNOTE-202 trial showing that BL-8040 plus Keytruda pembrolizumab led to a disease control rate (DCR) of 34.5%, including one partial response and nine cases...
12:32 PM, Oct 19, 2018  |  BC Week In Review | Financial News  |  Proposed Offerings

Reports say Innovent seeking $422M IPO in Hong Kong

Innovent Biologics Inc. (Suzhou, China) did not respond to inquiries regarding reports that the company is seeking to raise $422 million in an IPO on the Hong Kong stock exchange, which would value the company...
12:14 PM, Oct 19, 2018  |  BC Week In Review | Company News  |  Deals

HiFiBiO Therapeutics acquires H-Immune

HiFiBiO Therapeutics (Cambridge, Mass.) acquired H-Immune Therapeutics S.A.S. (Paris, France) for an undisclosed sum. H-Immune is developing a pipeline of immuno-oncology focused human antibodies generated using the company's in vitro immunization platform. The biotech spun...
11:37 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Deals

AbbVie, Morphic partner on antifibrotic integrins

AbbVie Inc. (NYSE:ABBV) agreed to pay Morphic Therapeutic (Waltham, Mass.) $100 million up front for exclusive options to license antifibrotic integrins to block transforming growth factor β (TGFβ) activation via multiple undisclosed targets. Morphic is responsible...
11:34 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Apellis pauses Phase III trials after single lot of APL-2 causes inflammation

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) voluntarily paused dosing in Phase III trials of intravitreal APL-2 to treat geographic atrophy due to eight reported cases of non-infectious inflammation in patients treated from a single manufacturing lot of...
11:33 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Deals

SQZ, Roche expand deal to jointly develop cancer cell therapies

SQZ Biotechnologies Co. (Watertown, Mass.) and Roche (SIX:ROG; OTCQX:RHHBY) expanded a 2015 deal to co-develop and commercialize antigen presenting cell (APC) therapies to treat cancers that are difficult to address with other adoptive cell therapy...
11:27 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Other News

Roche culls pipeline, cuts include in-licensed, acquired programs

Roche (SIX:ROG; OTCQX:RHHBY) announced in its 3Q18 earnings it discontinued development of five new molecular entities, including Phase II rheumatoid arthritis candidate RG6125 (SDP051), plus two programs in development for follow-on indications. The pharma lost...

Pages